Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Arctic Pharma CEO Talks Early-Stage Research
Posted on December 27th, 2016 by Betsy Davis in Pharma R&D
One of the amazing things about doing early-stage research is that it can often take you in unexpected directions. Claudia Bøen was working as a scientist on developing a male contraceptive for Spermatech when their team found that a compound they were working with killed certain cancer cells. Now, Bøen is the CEO of a spin-off company, Arctic Pharma, which is pursuing that research in the hopes of developing innovative anti-cancer drugs.
Arctic Pharma recently became a part of Elsevier’s exciting new incubator program, The Hive, which is designed to empower a selected few of the most promising biotech start-ups with cutting-edge information and industry exposure. Bøen is pleased that being a part of The Hive will give her company access to Elsevier’s R&D Solutions, which she believes will assist them in making decisions on lead compound selection while also reducing search time and boosting productivity.
Read this interview with Claudia Bøen to learn more about her background as a scientist, her challenges as an entrepreneur and CEO, and to find out the details of Arctic’s technology and current pipeline.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Strategic Marketing Manager
- AI Can Work Wonders, But Can It Create Miracle Cures?
- Cancer-killing combo: Viagra and the flu vaccine
- When Looking to Accelerate the Pace of Research, Having the Right Multidisciplinary Tools Matters
- Big Talks on Big Data are Coming to Bio IT World
- Introducing the Hive’s newest class of innovative start-ups